Copenhagen - Delayed Quote DKK

Genmab A/S (GMAB.CO)

Compare
1,607.50
+1.50
+(0.09%)
At close: January 10 at 4:59:48 PM GMT+1
Currency in DKK All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
19,844,000.00
16,474,000.00
14,505,000.00
8,417,000.00
10,111,000.00
Cost of Revenue
774,000.00
226,000.00
--
--
--
Gross Profit
19,070,000.00
16,248,000.00
14,505,000.00
8,417,000.00
--
Operating Expense
12,507,000.00
10,927,000.00
8,238,000.00
5,464,000.00
3,798,000.00
Operating Income
6,563,000.00
5,321,000.00
6,267,000.00
2,953,000.00
6,313,000.00
Net Non Operating Interest Income Expense
994,000.00
912,000.00
303,000.00
184,000.00
174,000.00
Other Income Expense
-988,000.00
-596,000.00
375,000.00
781,000.00
-583,000.00
Pretax Income
6,569,000.00
5,637,000.00
6,945,000.00
3,918,000.00
5,904,000.00
Tax Provision
1,867,000.00
1,285,000.00
1,493,000.00
961,000.00
1,146,000.00
Net Income Common Stockholders
4,702,000.00
4,352,000.00
5,452,000.00
2,957,000.00
4,758,000.00
Diluted NI Available to Com Stockholders
4,702,000.00
4,352,000.00
5,452,000.00
2,957,000.00
4,758,000.00
Basic EPS
72.85
66.64
84.45
46.00
73.00
Diluted EPS
72.34
66.02
83.65
45.54
72.21
Basic Average Shares
64,639.14
65,309.74
65,783.13
65,634.30
65,179.01
Diluted Average Shares
65,109.34
65,914.71
66,009.60
66,045.75
65,885.88
Total Operating Income as Reported
6,294,000.00
5,321,000.00
6,267,000.00
2,953,000.00
6,313,000.00
Total Expenses
13,281,000.00
11,153,000.00
8,238,000.00
5,464,000.00
3,798,000.00
Net Income from Continuing & Discontinued Operation
4,702,000.00
4,352,000.00
5,452,000.00
2,957,000.00
4,758,000.00
Normalized Income
5,409,196.83
4,812,136.95
5,157,615.55
2,367,562.28
5,227,836.38
Interest Income
1,038,000.00
939,000.00
324,000.00
197,000.00
184,000.00
Interest Expense
44,000.00
27,000.00
21,000.00
13,000.00
10,000.00
Net Interest Income
994,000.00
912,000.00
303,000.00
184,000.00
174,000.00
EBIT
6,613,000.00
5,664,000.00
6,966,000.00
3,931,000.00
5,914,000.00
EBITDA
6,969,000.00
5,959,000.00
7,328,000.00
4,179,000.00
6,173,000.00
Reconciled Cost of Revenue
774,000.00
226,000.00
--
--
--
Reconciled Depreciation
356,000.00
295,000.00
362,000.00
248,000.00
259,000.00
Net Income from Continuing Operation Net Minority Interest
4,702,000.00
4,352,000.00
5,452,000.00
2,957,000.00
4,758,000.00
Total Unusual Items Excluding Goodwill
-988,000.00
-596,000.00
375,000.00
781,000.00
-583,000.00
Total Unusual Items
-988,000.00
-596,000.00
375,000.00
781,000.00
-583,000.00
Normalized EBITDA
7,957,000.00
6,555,000.00
6,953,000.00
3,398,000.00
6,756,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-280,803.17
-135,863.05
80,615.55
191,562.28
-113,163.62
12/31/2020 - 10/20/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BAVA.CO Bavarian Nordic A/S
201.60
-0.84%
 
ZEAL.CO Zealand Pharma A/S
735.00
+0.07%
 
ALK-B.CO ALK-Abelló A/S
153.00
-0.26%
 
GUBRA.CO Gubra A/S
666.00
-1.48%
 
FLUO.ST FluoGuide A/S
46.70
-2.91%
 
HNSA.ST Hansa Biopharma AB (publ)
34.78
-0.69%
 
EVAX Evaxion Biotech A/S
0.9000
-2.17%
 
SANION.ST Saniona AB (publ)
6.80
-3.00%
 
PILA.ST Pila Pharma AB (publ)
4.5700
-2.97%
 
AVXL Anavex Life Sciences Corp.
11.23
-1.75%